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A B S T R A C T
The aim of the study was to describe the relationship of clinical outcome after percutaneous coronary intervention
(PCI) with stenting and genetic polymorphisms (GP) which are known to relate to the incidence of in-stent restenosis and
late thrombotic complications. The study included 190 patients with standardized clinical follow-up over 5 years, which
were initially treated with PCI. We investigated clinical data, angiographic characteristics, 10 polymorphisms involved
in neointimal hyperplasia and late thrombosis at 6 different levels and their relationship with the major adverse cardiac
events (MACE). The long term clinical outcome was defined by MACE: death, target vessel revascularization (PCI or cor-
onary bypass grafting, CABG) and myocardial infarction. Angiotensin receptor type I (AGTR A1166C) and angioten-
sinogen (AGT MET235THR) GPs correlated with repeat revascularization and total MACE. Carriers of G allele for
NOS3 A922G GP were shown to have a significantly lower repeat revascularization rate in comparison with the AA ge-
notype, as did the T allele carriers in the NOS3 C690T GP analysis when compared to the CC genotype. The Asp genome
carriers with the NOS3 GLU298ASP GP were also shown to have significantly less re-PCI in contrast to the Glu/Glu ge-
notype. The study could document the protective influence of the 4G/5G GP for plasminogen inhibitor activator-1, which
carried the lowest rate of re-PCI and total MACE during the follow-up. GPs for b-1 G-protein subunit GNB3 C825T,
fibrinogen FGB G455A and E-selectins Ser128Arg and Leu554Phe did not show statistical correlation with the clinical
outcome. The results illustrate the potential use of genetic markers in defining patients with possibly worse clinical out-
come after PCI, who may profit from more aggressive prevention of restenosis and late thrombotic complications.
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Introduction
PCI with stenting currently represents the dominant
method for treating patients acute and symptomatic cor-
onary artery disease. Two issues dominate the clinical
course after stent placement: in-stent restenosis (ISR)
and late stent thrombosis (LST). The latter has recently
raised particular interest of the interventional cardio-
logic community, since it was questioned in relation with
the safety of drug-eluting stent (DES) placement1.
Restenosis, defined as »artery healing after injury
cause by the transluminal coronary revascularization«2
has been the main problem since the introduction of cor-
onary angioplasty and stenting. The cause of ISR is
intimal hyperplasia based on migration and proliferation
of cells originating in the vessel intima. Evolution of
restenosis is a complex and not completely understood
process. Well known clinical (diabetes) and angiographic
(stent length, vessel diameter, bifurcations, complex le-
sions, total occlusions) predictors do not account for all
cases.
There is a vast amount of data on the pivotal role that
genetic polymorphisms play in the pathogenesis of a vari-
ety of diseases3–5. Although numerous genetic markers
have been implicated as risk factors for ISR, there are a
significant proportion of those who are thought to have
protective influence in these patients6,7. Several studies
have dealt with the role of the renin-angiotensin-aldo-
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sterone system (RAAS) and possible beneficial influence
of ACE inhibitors with respect to ISR8-11. G-protein poly-
morphisms have also been investigated in this context,
since these molecules play an important role in signal
transmission involved in vascular cell proliferation and
platelet aggregation12,13. Nitric oxide synthase (eNOS)
promotes production of nitric oxide (NO) in endothelial
cells, which in turn acts as an atheroprotective molecule,
due to inhibition of vascular smooth cell proliferation,
control of extracellular matrix and regulation of throm-
botic and inflammatory vessel wall reaction14-17. Further-
more, NO deficiency is related to thrombosis and resteno-
sis at the site of vascular injury inflicted by percutaneous
interventions18. Fibrinolysis, particularly the plasmino-
gen activator inhibitor (PAI-1), is also linked to the
ISR19, as is shown by experimental and clinical data deal-
ing with fibrinolysis disorders after PCI20-25. Increased
level of fibrinogen is generally considered as a risk factor
for cardiovascular events26,27, but it was also demon-
strated that is may be linked to increased incidence of
ISR28. Mononuclear cell adhesion represents one of the
earliest stages of atherosclerosis and selectins, such as
E-selectin, play a prominent role in interaction between
leucocytes, endothelial cells and platelets. Increased SES
levels were noted in patients who developed restenosis
after peripheral angioplasty and coronary stenting29,30.
Occurrence of complications during long-term fol-
low-up after PCI in a real-world setting is typically evalu-
ated by investigating the rate of major adverse cardiac
events (MACE). These include death, repeat revascula-
rization of the target vessel (either by repeat PCI or by
coronary bypass grafting, CABG) and myocardial infarc-
tion. Repeat revascularization is more likely to be related
to the issue of ISR, whereas death and myocardial infarc-
tion raise the suspicion of LST.
Since very few published data addressed the mutual
relationship of several polymorphisms in terms of their
influence on ISR and LST, and the majority of published
data did not include a long-term clinical follow-up, we ex-
plored these issues with the genetic data obtained in our
PCI patients. This is of particular importance since the
dominant strategies to manage and prevent these issues,
including elective placement of drug-eluting stents (DES)
and prolonged and/or intensified dual antiplatelet treat-
ment (acetylsalicylic acid + clopidogrel) may be of lim-
ited availability and occasionally carry potential risks.
Subjects and Methods
Patients
A total of 205 consecutive patients admitted to »Mag-
dalena« Hospital for Cardiovascular Surgery and Cardi-
ology, Department of Cardiology, Krapinske Toplice, Cro-
atia were included in this study. The PCI was performed
in a standardized manner in all patients, as indicated by
their clinical status (stable coronary disease, excluding
patients with acute myocardial infarction). All patients
received bare metal stents (BMS). Postprocedural ther-
apy did not differ between patients and all had signed an
informed consent for the procedure and the additional
blood sampling related to genetic markers which were
analyzed in this study. Clinical parameters were recorded
for all patients, including age, sex, risk factors (diabetes
according to WHO definition, arterial hypertension, smo-
king, hypercholesterolemia) and previous myocardial in-
farction.
PCI parameters
Periprocedural stenting data included number of ves-
sels with significant stenosis (N), number of lesions (N),
number of implanted stents (N), total length of stented
segment (mm), average stent diameter (mm). Ejection
fraction of the left ventricle (LVEF, %) and presence of
chronic total occlusion (CTO) were also noted.
Clinical follow-up
There were two main procedures to obtain the fol-
low-up data. For those patients who were readmitted to
the hospital during the follow-up period, data were scree-
ned from their hospital charts. The follow-up data for pa-
tients who were not readmitted was obtained by means
of a standardized transtelephonic contact. The follow-up
data included time to occurrence of first major adverse
cardiac event (in days), type of MACE (death, revascu-
larization – re-PCI or CABG, and myocardial infarction).
The follow-up period for all patients was greater than 5
years. Death was recorded if it was by certain or probable
cardiac cause.
Determination of genetic markers
Peripheral blood was sampled after obtaining prior
written informed consent. DNA was extracted and fur-
ther processed by polymerase chain reaction (PCR). The
methods for determining genetic polymorphisms were
previously described elsewhere31. The results of the fol-
lowing genetic polymorphism analysis were used in this
study: AGTR1 A1166C, GNB3 C825T, PAI1 5G/4G,
NOS3 A(-922)G, NOS3 C(-690)T, NOS3 GLU298ASP,
AGT MET235THR, SELE SER128ARG, SELELEU-
554PHE, FGB G(-455)A. The clinical outcome variables
(MACE, i.e. re-PCI, CABG, IM, death) were then ana-
lyzed with respect to specific genetic polymorphisms.
Statistical analysis
Discrete variables were expresses as whole numbers
or percentage and compared using chi-square or Fisher
exact test. Continuous variables were expressed as me-
dian value ± standard deviation and compared using two
sample t-test or variance analyses for more than two
groups. P value of less than 0.5 was considered statisti-
cally significant.
Ethical considerations
This study was approved in 2004 by the Ethics com-
mittee of the »J. J. Strossmayer« University, School of
Medicine, and by the Ethics committee of the »Magdale-
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na« Hospital for Cardiovascular Surgery and Cardiology,
Department of Cardiology, Krapinske Toplice, Croatia
Results
190 out of 205 patients (92.7%) completed the fol-
low-up and qualified for statistical analysis. MACE data
for all patients were obtained 5 years after the initial
PCI, so that all patients had a follow-up period of ³1,825
days. The mean value of follow-up period for patients
free of MACE was 1,917.4±214.1 days (range 1,825 to
2,187), whereas for the patients with one of the MACE it
was 701.3±600.6 days (1,825 to 1,945). This difference
was statistically significant.
Patient clinical and angiographic characteristics for
the two groups, according to total MACE are listed in Ta-
ble 1. Group 1 indicates patients who were free of MACE,
whereas group 2 includes patients who experienced one
of the MACE during the follow-up period. The incidence
of any MACE was 26.3% (N=50 patients). The groups
did not differ in clinical characteristics, except for diabe-
tes and previous myocardial infarction (although the lat-
ter was not reflected in difference in LVEF). The inciden-
ce of MACE was higher in patients with more diseased
vessels, more lesions and with smaller stent diameter; in-
terestingly, patients with PCI of CTO had fewer events
during the follow-up.
Table 2 shows the results genetic polymorphism anal-
ysis according to long-term clinical outcome. Follow-up
data have been grouped in by most likely event mecha-
nism. Repeat revascularization of the target vessel be-
cause of in-stent restenosis was related to re-PCI and
CABG, whereas late thrombotic complications and/or
disease progression were best described by death and
myocardial infarction.
The genetic marker for angiotensinogen II receptor
type I (AGTR A1166C) showed that C allele carriers have
statistically significant higher risk for re-PCI and MI, in
contrast to subjects without the C allele. With angio-
tensinogen polymorphism (AGT MET235THR), M allele
carriers (MM and MT, TM) showed significant differ-
ences in comparison with the TT genotype, with the M
allele carrier status conferring a higher risk for re-PCI,
combined outcome of re-PCI and CABG, as well as total
events during follow-up. Three genetic polymorphisms
for nitric oxide synthase were investigated. NOS3 A922G
marker showed significant difference between G allele
carriers and AA genotype with respect to revascula-
rization events (re-PCI, re-PCI + CABG). T allele carri-
ers in the NOS3 C690T polymorphism analysis had sig-
nificantly fewer major adverse cardiac events, in contrast
to CC genotype. NOS3 GLU298ASP marker study sho-
wed a protective influence for in-stent restenosis in Asp
carriers (they had significantly lower rate of re-PCI than
Glu/Glu genotype). However, presence of Asp allele was
an adverse factor for late thrombotic events or disease
progression, since these subjects had significantly higher
rate of the combined event of myocardial infarction and
death during the follow-up.
Results for the plasminogen activator inhibitor-1
marker (PAI1 5G/4G) showed significant difference for
the 4G5G genotype and re-PCI, total MACE (lowest rate)
and death (highest rate).
The genetic polymorphism analysis for the G-protein
b-1 subunit (GNB3 C825T), fibrinogen (FGB G455A)
and E-selectin (SELE Ser128Arg and SELE Leu554Phe)
did not show any significant differences for the observed
parameters.
Discussion
In terms of clinical characteristics, the results of this
study correspond with the well-known fact that diabetes
is a definite risk factor for an increased incidence of
MACE in patients after PCI with stenting. This could
also be documented in our results after more than 5
years of follow-up. However, albeit significant, the differ-
ence observed in our patient series (total MACE 20.0%
for diabetics vs. 16.4% for non-diabetics) was still less
prominent than is usually found in the literature. This is
explained by the revascularization indication policy, which
consistently favored surgery for diabetic patients and
this was particularly emphasized by the fact that the PCI
patient were scheduled to receive bare-metal and not
drug-eluting stents. Overall risk profile of study patients
did not differ significantly from the profile found in Cro-
atian coronary patients32.
The analysis of angiographic findings with respect to
the long-term outcome also showed the expected trend
for excess in MACE with patients who had multivessel
disease, more lesions and smaller stent diameter; how-
ever, this was not the case for total stent length and oc-
currence of CTO recanalization. The latter may be at-
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TABLE 1
CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS OF PCI
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tributed to the relatively small proportion of CTO pa-
tients, whereas the stenting tactics with consistent use of
high pressure inflation and relative oversizing may in
part explain the fact that the length of stented segment
did not significantly affect the long-term success.
With respect to the genetic markers involved in the
action of the renin-angiotensin-aldosterone system
(RAAS), there are reports that document that the poly-
morphism A1166C found in the 3'-non-coding region of
the gene for angiotensin II type I receptor in subjects
with CC genotype is linked to increased vasoconstriction
through a not yet well-understood mechanism33,34. Our
results support the fact that C allele carriers have an in-
creased risk for re-PCI and myocardial infarction; possi-
ble influence of concomitant ACE inhibitor therapy was
not subject of this investigation. The angiotensinogen
polymorphism analysis (AGT MET235THR) is also con-
sistent with prevalent data from the literature35. The
study by Toyofuku et al.36 showed that 235T homozy-
gotes experience a significant beneficial effect of ACE in-
hibitor therapy with respect to ISR. Indeed, our results
confirmed this observation, since they showed, irrespec-
tive of ACE inhibitor treatment, a protective influence of
the TT genotype in context of restenosis. Conversely, the
M allele represents a genetic risk factor and carries an in-
creased incidence of re-PCI, combined outcome of re-PCI
+ CABG, and total number of MACE during the fol-
low-up period.
Nitric oxide is a known factor in vascular tone con-
trol37,38, free superoxide radicals scavenger and inhibitor
of platelet aggregation, leukocyte adhesion and smooth
muscle cell proliferation39. One previous study with an-
other eNOS genetic marker40 showed that the TT ge-
nome was related to increased risk of death or myocar-
dial infarction, but not with clinical outcomes implying
in-stent restenosis (i.e. re-PCI or CABG). Our study dem-
onstrated similar results for the Asp genotype of the
NOS3 GLU298ASP polymorphism, since we could show
a protective effect on ISR in Asp carriers (they had signif-
icantly lower incidence of re-PCI than the Glu/Glu geno-
type). However, the presence of the Asp allele was shown
to be adverse factor for late thrombotic events, since
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TABLE 2
GENETIC POLYMORPHISMS OF PCI PATIENTS WITH STENT IMPLANTATION WITH RESPECT TO FOLLOW-UP OUTCOME
Genetic polymorphism
Patients MACE
N Re-PCI + CABG MI + death Total
Angiotensin II receptor– type I
AGTR A1166C
AA 100 (52.6%) 13 (13.0%)* 10 (10.0%) 23 (23.0%)
AC,CA + CC 90 (47.4%) 21 (23.3%) 6 (6.6%) 27 (29.9%)
Angiotensinogen AGT MET235THR MM + MT,TM 145 (76.3%) 28 (19.2%)* 13 (9.0%) 41 (28.3%)*
TT 45 (23.7%) 6 (13.3%) 3 (6.6%) 9 (19.9%)
G-protein b-1 subunit GNB3 C825T CC 91 (47.8%) 17 (18.7%) 8 (8.8%) 25 (27.5%)
CT,TC + TT 99 (52.2%) 17 (17.0%) 8 (8.0%) 25 (25.0%)
Nitric oxide synthase NOS3 A922G AA 76 (40.0%) 16 (21.1%) 6 (7.8%) 22 (28.9%)
AG, GA + GG 114 (60.0%) 18 (15.8%)* 10 (8.8%) 28 (24.6%)
NOS3 C690T CC 144 (75.8%) 14 (9.8%) 6 (7.8%) 43 (29.9%)
CT, TC + TT 46 (24.2%) 2 (4.4%)* 10 (8.8%) 7 (15.3%)*
NOS3 GLU298ASP Glu/Glu 97 (51.1%) 25 (25.7%) 6 (6.2%)* 31 (31.9%)
Glu/Asp+Asp/Asp 93 (48.9%) 9 (9.7%)* 11 (11.8%)* 20 (21.5%)*
Plasminogen inhibitor activator-1
PAI1 5G/4G
4G4G 42 (22.1%) 10 (23.8%) 4 (9.5%) 14 (33.3%)
4G5G 101 (53.2%) 15 (14.9%)* 9 (8.9%) 24 (15.0%)*
5G5G 47 (24.7%) 9 (19.1%) 3 (6.4%) 12 (25.5%)
Fibrinogen FGB G455A GG 107 (56.3%) 18 (16.8%) 10 (9.4%) 28 (26.2%)
GA, AG + AA 83 (43.7%) 16 (19.3%) 6 (7.2%) 22 (26.5%)
E-selectin SELE Ser128Arg Ser/Ser 154 (81.1%) 30 (19.4%) 12 (7.7%) 42 (27.1%)
Ser/Arg 35 (18.4%) 4 (11.4%) 4 (11.4%) 8 (22.8%)
Arg/Arg 1 (0.5%) – – –
SELE Leu554Phe Leu/Leu 170 (89.5%) 31 (18.2%) 14 (8.2%) 45 (26.4%)
Leu/Phe 20 (10.5%) 3 (15.0%) 2 (10.0%) 5 (25.0%)
MACE are grouped by most likely mechanism (re-PCI + CABG – ISR vs. MI + death – LST and/or disease progression); PCI =
percutaneous coronary intervention; MACE = major adverse coronary events; re-PCI = repeat percutaneous coronary intervention;
CABG = coronary artery bypass grafting; MI = myocardial infarction; LST = late stent thrombosis. *p<0.05.
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these subjects had an excess of combined outcome of in-
farction and death in the long-term follow-up. Neverthe-
less, because of the prevalent share of re-PCI in total
MACE, this was still linked with favorable outcome.
Our results indicate that the polymorphism of the
4G5G gene for plasminogen activator inhibitor-1 (PAI-1)
is associated with reduced incidence of ISR. This data is
consistent with previous observations41, however, there
are in sharp contrast with one earlier study, which found
no association between outcome after stenting and ge-
netic profile for PAI-142. Nevertheless, pathophysiologic
mechanism does provide a basis for the role of PAI-1 in
development of ISR. PAI-1 is considered an important
factor in thrombosis initiation and myocardial infarc-
tion; on the other hand, the pathophysiologic processes
of healing are similar to those involved in ISR43. Data
from our investigation suggest that PAI-1 may play a role
in prediction of ISR, namely that the 4G5G polymor-
phism variant is associated with decreased incidence of
re-PCI as clinical outcome.
In our series we found no correlation between genetic
markers for G-protein b-1 subunit and fibrinogen44, so
we conclude that these polymorphisms are less likely to
be used for possible detection of patients who will de-
velop restenosis and/or late thrombotic event after PCI.
In contrast, previous studies have shown that the 128Arg
allele for E-selectin is related to premature atherosclero-
sis45 and early onset of coronary artery disease46. In gen-
eral, the relationship between E-selectin polymorphisms
and de novo atherosclerotic lesions, as well as lesions
that occur after interventional procedures, may be linked
to the well known role of E-selectin on interactions of en-
dothelial cells. The family of selectin adhesion molecules
participates in leukocyte turnover and is essential for
leukocyte adhesion at the site of inflammatory reaction.
Selectins are considered fundamental for regulating the
immunologic response of injured endothelial cells47.
However, the results of this study do not support the re-
lationship between investigated polymorphisms for E-se-
lectin and clinical outcome, which stands in contrast to
findings in the literature. With respect to conflicting re-
sults for genetic markers of atherosclerosis, this is not an
uncommon finding in the literature48. Our results could
be interpreted by distribution of genes in this specific
population, although we may conclude that these genes
may not be used as reliable markers for clinical outcome
in this group of patients.
This study investigated the relation of clinical out-
come to a total of 10 genetic polymorphisms which repre-
sent pathophysiologic mechanisms on 6 different levels
included in processes of in-stent restenosis and late
thrombotic events. Re-PCI and CABG were primarily
clinical events linked with ISR, whereas death and myo-
cardial infarction are manifestations of late thrombotic
events or progression of underlying coronary disease.
In conclusion, genetic polymorphisms may be assig-
ned in two groups with respect to their clinical outcome
after PCI:
Positive influence Negative influence
AA genotype of AGTR A1166C
polymorphism
M allele carriers in
AGT MET235THR
G allele carriers of NOS3 A922G
polymorphism
Carriers of T allele in NOS3 C690T
polymorphism analysis
Carriers of Asp genome in NOS3
GLU298ASP polymorphism
4G/5G polymorphism for plasminogen
inhibitor activator-1
Interactive effects of multiple genetic factors and en-
vironmental influence on final phenotype of the complex
pathological entity of coronary artery disease treated
interventionally with stents reflect the general complex-
ity of processes in cardiovascular medicine, so that surely
further studies with more patients will be needed in or-
der to confirm the findings of this study as relevant for
clinical practice. The final result of such investigations
could certainly mean identification of those genetic pre-
dictors which will reliably determine the clinical outcome
after PCI.
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POVEZANOST GENSKIH BILJEGA ATEROSKLEROZE I DUGORO^NOG ISHODA
NAKON PERKUTANE KORONARNE INTERVENCIJE SA STENTOM
S A @ E T A K
Cilj ovog ispitivanja bio je opisati povezanost klini~kog ishoda nakon perkutane koronarne intervencije (PCI) sa
stentom i genskih polimorfizama (GP) za koje je poznato da su u odnosu s incidencijom in-stent restenoze i kasnih
trombotskih komplikacija. Ispitivanje je uklju~ilo 190 bolesnika sa standardiziranom klini~kim pra}enjem tijekom vi{e
od 5 godina, koji su inicijalno lije~eni s PCI. Ispitivali smo klini~ke podatke, angiografske zna~ajke, 10 polimorfizama
koji su povezani s neointimalnom hiperplazijom i kasnom trombozom na 6 razli~itih razina te njihov odnos s glavnim
ne`eljenim kardijalnim doga|ajima (MACE). Dugoro~ni klini~ki ishod bio je definiran pomo}u MACE: smrt, revaskula-
rizacija ciljne `ile (PCI ili koronarne premosnice, CABG) i infarkt miokarda. GP-i za angiotenzinski receptor tipa I
(AGTR A1166C) i angiotenzinogen (AGT MET235THR) bili su povezani s ponovno revaskularizacijom i ukupnim
MACE. Dokazano je da nositelji G alela za NOS3 A922G GP imaju zna~ajno ni`u stopu ponovne revaskularizacije u
usporedbi s AA genotipom, {to je bio slu~aj i s nositeljima T alela u analizi NOS3 C690T GP-a, u usporedbi s CC geno-
tipom. Tako|er je dokazano da nositelji Asp genoma u NOS3 GLU298ASP GP-u imaju zna~ajno manje re-PCI, za razli-
ku od Glu/Glu genotipa. Ispitivanje je dokumentiralo i za{titni utjecaj 4G/5G GP-a za inhibitor aktivatora plazminoge-
na-1, koji je bio povezan s najni`om stopom re-PCI i ukupnih MACE tijekom pra}enja. GP-i za b-1 G-protein podjedinicu
GNB3 C825T, fibrinogen FGB G455A i E-selektine Ser128Arg i Leu554Phe nisu pokazali statisti~ku korelaciju s kli-
ni~kim ishodom. Rezultati opisuju mogu}u primjenu genskih biljega u odre|ivanju bolesnika s vjerojatnim lo{ijom isho-
dom nakon PCI, koji bi mogli imati koristi od agresivnije prevencije restenoze i kasnih trombotskih komplikacija.
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